Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Mexico Tech Monitor.
Press releases published on August 7, 2025
Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 7, 2025
Investigational new drug (IND) application cleared by the United States Food and Drug Administration (FDA) for ZW251 with first-in-human studies planned to initiate in 2025 China and European approval for zanidatamab in 2L HER2-positive biliary tract …
NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 7, 2025
Announced strategic partnership with Simcere Zaiming for Phase 1 program SIM0505 (CDH6 ADC) with plans to dose the first SIM0505 patient in the United States this quarter Currently in cohort 4 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers …
Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 7, 2025
Cash runway extending into the fourth quarter of 2026 with no debt, funding current clinical programs through to their next data milestone Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- …
Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update
GlobeNewswire
·
August 7, 2025
– Announced strategic research collaboration with Chugai for two undisclosed molecules – – Presented preclinical data demonstrating bioequivalence of novel, bispecific GLP-1/GLP-2 receptor agonist delivered orally via RaniPill (RT-114) compared to …
Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 7, 2025
Q2 2025 product sales of $18.9 million, representing 108% growth over Q2 2024 and the 18th straight quarter of sequential product sales growth Q2 2025 basic and fully diluted GAAP EPS of $(0.10), non-GAAP fully diluted EPS of $0.03, and Adjusted EBITDA of …
Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress
GlobeNewswire
·
August 7, 2025
Positive topline Phase 2a biomarker data position VTX3232 as a potential disease-modifying therapy for patients with Parkinson’s disease Data from the Phase 2 study of VTX2735 in patients with recurrent pericarditis expected in Q4 2025 Phase 2 study of …
89bio Reports Second Quarter 2025 Financial Results and Corporate Updates
GlobeNewswire
·
August 7, 2025
– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 topline histology data expected in 1H 2027 and in 2028, respectively; each trial designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis (MASH) – …
Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 7, 2025
CANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and …
AvePoint Announces Second Quarter 2025 Financial Results
GlobeNewswire
·
August 7, 2025
Total quarterly revenue surpassed $100 million for the first time Second quarter SaaS revenue of $77.3 million, representing 44% year-over-year growth, 40% on a constant currency basis Second quarter Total revenue of $102.0 million, representing 31% year- …
Synaptics Reports Fourth Quarter and Full Year Fiscal 2025 Results
GlobeNewswire
·
August 7, 2025
Fiscal 2025 revenue grew 12.0%, fueled by 53% growth in Core IoT product sales Synaptics' Board of Directors approved a new share repurchase program of up to $150 million Fiscal 2025 Financial Highlights Revenue of $1.074 billion increased 12% year-over- …
Key Tronic Corporation Announces Fourth Quarter Reporting and Annual Meeting Date
GlobeNewswire
·
August 7, 2025
SPOKANE VALLEY, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Key Tronic Corporation (Nasdaq: KTCC), announced today that it plans to report its results for the fourth quarter and full year ended of fiscal 2025 after market close on August 27, 2025. Key Tronic …
scPharmaceuticals Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 7, 2025
Generated net FUROSCIX® revenue of $16 million in the second quarter of 2025; up 99% over Q2 2024 Doses shipped to patients increased 45% over Q1 2025 and 117% over Q2 2024 Launch of FUROSCIX in chronic kidney disease Autoinjector remains on track for sNDA …
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025
GlobeNewswire
·
August 7, 2025
$60.0M in 2Q25 Total Product Revenue More than 100 Patients Treated with Amtagvi® in 2Q25 Strategic Restructuring Extends Cash Runway into 4Q26 FY25 Total Product Revenue Guidance of $250M-$300M Reiterated SAN CARLOS, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) …
Galapagos Creates New Subscription Right Plan
GlobeNewswire
·
August 7, 2025
Mechelen, Belgium; August 7, 2025, 22.01 CET; regulated information – Galapagos NV (Euronext …
Galapagos creëert nieuw inschrijvingsrechtenplan
GlobeNewswire
·
August 7, 2025
Mechelen, België; 7 augustus 2025, 22.01 CET; gereglementeerde informatie – Galapagos NV (Euronext …
Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 7, 2025
Strong execution and continued progress across pipeline Unprecedented data delivered from Phase 2 CSU study demonstrating profound, sustained complete response and improved quality of life 7 months after completion of barzolvolimab dosing Data anticipated …
Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update
GlobeNewswire
·
August 7, 2025
Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025 Patient enrollment in Skye’s CBeyondTM Phase 2a obesity trial extension study initiated Independent Data Safety Monitoring Committee completed fourth …
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 7, 2025
Soquelitinib data from cohort 3 of atopic dermatitis Phase 1 clinical trial demonstrates earlier and deeper responses compared to cohorts 1-2 along with clinically meaningful reduction in itch as early as day 8 Enrollment ongoing in Phase 1 trial extension …
Apyx Medical Corporation Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 7, 2025
Successfully launched AYON Body Contouring System™ to key surgeons in critical geographies; plan for commercial launch in September 2025 Initiated commercial sales of Renuvion® in China with strong clinical interest and completed initial procedures Based …
Turtle Beach Corporation Announces Second Quarter 2025 Financial Results and Reiterates Full Year Guidance
GlobeNewswire
·
August 7, 2025
–Delivered Net Revenue of $56.8 Million– –Gross Margin Improved to 32.2%, an Increase of 200 Basis Points Compared to Prior Year– –Net Loss of $2.9 Million Compared to Net Loss of $7.5 Million in Prior Year– –Adjusted EBITDA of ($3.0) Million– –Refinanced …